Teva Debuts US Azopt Rival
Brinzolamide 1% Ophthalmic Suspension Developed And Manufactured By Indoco
Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.
You may also be interested in...
India’s Indoco saw its international business grow after Teva launched the Indoco-manufactured and developed first US generic version of Novartis’ Azopt (brinzolamide) 1% solution. Though the company saw muted domestic growth, it aims to bolster its overall performance by launching 20 products a year by 2023.
Forecasting up to a dozen complex generic launches by Teva in the US in 2021, executive vice-president for North America commercial Brendan O’Grady said Teva was continuing to push for changes to boost approval rates ahead of GDUFA III next year.
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.